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Abstract
Background: Estimating equations are recommended by clinical guidelines as the preferred method for assessment of
glomerular filtration rate (GFR). The aim of the study was to compare population-based prevalence estimates of decreased
kidney function in Germany defined by an estimated GFR (eGFR) <60 ml/min/1.73m2 using different equations.
Methods: The study included 7001 participants of the German Health Interview and Examination Survey for
Adults 2008–2011 (DEGS1) for whom GFR was estimated using the Modification of Diet in Renal Disease study
equation (MDRD), the revised Lund-Malmö equation (LM), the Full Age Spectrum creatinine equation (FAScre),
the Chronic Kidney Disease Epidemiology Collaboration equations with creatinine and cystatin C (CKD-EPIcrecys),
with creatinine (CKD-EPIcre) and with cystatin C (CKD-EPIcys). Bland-Altman plots were used to evaluate the
agreement between the equations.
Results: Prevalence estimates of decreased kidney function were: 2.1% (CKD-EPIcys), 2.3% (CKD-EPIcrecys), 3.8%
(CKD-EPIcre), 5.0% (MDRD), 6.0% (LM) and 6.9% (FAScre). The systematic differences between the equations were
smaller by comparing either equations that include serum cystatin C or equations that include serum creatinine
alone and increased considerably by increasing eGFR.
Conclusions: Prevalence estimates of decreased kidney function vary considerably according to the equation
used for estimating GFR. Equations that include serum cystatin C provide lower prevalence estimates if compared
with equations based on serum creatinine alone. However, the analysis of the agreement between the equations
according to eGFR provides evidence that the equations may be used interchangeably among persons with
pronounced decreased kidney function. The study illustrates the implications of the choice of the estimating
equation in an epidemiological setting.
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Background
Chronic Kidney Disease (CKD) is defined by morpho-
logical and functional damage to the kidney [1, 2].
Clinical assessment of kidney function is central to the
routine clinical practice [3, 4] and glomerular filtration
rate (GFR) is the best overall index-indicator of
excretory kidney function in health and disease [3, 5]. In
the epidemiological setting, decreased kidney function
may be defined by a GFR <60 ml/min/1.73m2 [1]. As
directly measuring GFR is often cumbersome in routine
clinical practice, researchers have developed and vali-
dated several GFR estimating equations that include
demographic and clinical variables as surrogates for
muscle mass and unmeasured factors that affect serum
creatinine level, such as age, sex and race. Some of these
equations are meanwhile recommended by clinical
guidelines as the preferred method for assessment of
GFR in the routine clinical care [1].
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Decreased kidney function has been shown to be an
independent marker for major adverse outcomes of
CKD, including progression to end-stage kidney failure
and premature death caused by cardiovascular disease
[6–8]. Patients with decreased kidney function require
considerable medical attention to prevent deterioration
and the development of complications. If kidney disease
progresses to end-stage kidney disease, renal replace-
ment therapy is an enormously resource consuming
condition. Given its high impact on patients’ quality of
life and medical resources and rising prevalence esti-
mates reported from many countries [9], CKD is in-
creasingly recognized a major public health problem and
the knowledge of its prevalence is of great importance
from both a medical and the economical standpoint.
Several studies evaluated performance and limitations of
different estimating equations for GFR against a gold
standard of kidney function testing in a clinical setting
[4, 10–14]. Although it is widely known to nephrologist
that the eGFR equations perform differently in relation
to patient characteristics, the behavior of the equations
in unselected large population-based samples has only
been investigated in detail in the NHANES study to our
knowledge. Therefore, a detailed assessment of the be-
havior of the equations in a European, predominantly
Caucasian population of 7000 participants is important
for researchers who want to provide population-based
prevalence estimates of kidney dysfunction. To date, lit-
erature about the prevalence of kidney function in
Germany is scarce. Recently, we published population-
based estimates of prevalence of kidney damage in
Germany based on measures of albuminuria and the use
of an established equation for GFR estimation [15]. Fur-
thermore, the Study of Health in Pomerania (SHIP-1)
and the Cooperative Health Research in the Region of
Augsburg (KORA F4) reported results about prevalence
of decreased kidney function in Northeast and Southern
Germany respectively [16]. Finally, the Berlin Initiative
Study assessed kidney function in Berlin in a cross sec-
tional analysis of people aged 70 years and older [17].
The present study compares different population-based
prevalence estimates of decreased kidney function
among adults in Germany using six different GFR esti-
mating equations.
Methods
Study population and design
The German Health Interview and Examination Survey
for Adults (“Studie zur Gesundheit Erwachsener in
Deutschland”, DEGS) is part of the health monitoring
system at the Robert Koch-Institute (RKI). The concept
and design of DEGS are described in detail elsewhere
[18–20]. The first wave (DEGS1) was conducted from
2008 to 2011 and included interviews, examinations and
tests. The DEGS1 study has a mixed design, which en-
ables both cross-sectional and longitudinal analyses. For
this purpose, a random sample from local population
registries was drawn to supplement former participants
from the German National Health Interview and Exam-
ination Survey 1998 (GNHIES98). To evaluate kidney
function, blood samples were taken from all participants
and serum creatinine concentration (Architect, Abbott
Diagnostics, Wiesbaden; IDMS traceable creatinine Assay,
kinetic Jaffe’s method) and serum cystatin C concentration
(N Latex Cystatin C assay, Prospec, Siemens Healthcare,
Eschborn) were measured. Participants with diabetes mel-
litus were identified according to self-reported medical
history and verified current use of anti-diabetic drugs [21].
Participants with gestational diabetes were not included
among those with diabetes mellitus. Arterial hypertension
was assumed if the participant reported current treatment
with antihypertensive medications or elevated blood pres-
sure (≥140 mmHg systolic or ≥90 mmHg diastolic) was
measured in the survey [22].
The analyses presented here refer to the sample of
7001 participants of the DEGS1 aged 18–79 years for
whom estimated GFR (eGFR) was calculated using six
GFR estimating equations (creatinine was measured in
mg/dl, cystatin C in mg/l): the isotope dilution mass
spectrometry traceable Modification of Diet in Renal
Disease study equation (MDRD) [23], the revised Lund-
Malmö equation (LM) [12], the Full Age Spectrum cre-
atinine equation (FAScre) [24], the Chronic Kidney Dis-
ease Epidemiology Collaboration creatinine equation
(CKD-EPIcre), the Chronic Kidney Disease Epidemi-
ology Collaboration cystatin C equation (CKD-EPIcys)
and the Chronic Kidney Disease Epidemiology Collabor-
ation creatinine and cystatin C equation (CKD-EPI-
crecys) [4]. Equations are detailed in Fig. 1. Persons with
missing data on eGFR were excluded (N = 114).
Statistical analysis
Participants were classified into four GFR categories
based on the estimated GFR values (expressed in ml/
min/1.73m2) as follows: G1 (≥90), G2 (60 < 90), G3a (45
< 60) and G3b-G5 (<45). We estimated the prevalence
and corresponding 95% confidence intervals (95% CI) of
a decreased kidney function, as defined by an eGFR
<60 ml/min/1.73m2, and the prevalence of each GFR
category. Furthermore, we calculated the population
based estimate of the number of persons with decreased
kidney function in Germany using the population census
figures of the Federal Republic of Germany in 2011.
Population data were provided by the Federal Bureau of
Statistic.
We evaluated the agreement between the six equations
used for estimating GFR according to the approach pro-
posed by Bland and Altman [25]. Bland-Altman plots
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display for each person the difference between two mea-
surements against their mean. To compare the equations
with each other, the absolute mean difference (md) be-
tween eGFR was used as a measure of the magnitude of
the systematic difference (bias) between the equations.
In addition, as a measure of relative change of eGFR, we
calculated the mean percent difference between the
measurements. The limits of the agreement between the
equations were defined as md ±1.96 standard deviation
of the differences (SD) and were used as a measure of
the variability of the bias. These values represented the
range within which 95% of the differences were included
(95% CI agreement). Furthermore, for each of the ten
pairwise comparisons, the analysis of the md was strati-
fied by the GFR category based on the mean value of
eGFR (G1: ≥90, G2: 60 < 90, G3a: 45 < 60, G3b-G5: <45).
Prevalence estimates were weighted by a factor that
corrects sample deviations from population structure (as
of 31 Dec. 2010) with regard to age, sex, region and
nationality, type of community and education. When
calculating the weighting factor for previous participants
of GNHIES98, the probability of repeated participation,
based on a multivariable logistic model, was taken into
account. A non-response analysis and a comparison of
selected indicators with data from official statistics indi-
cate a high level of sample representativeness for the
resident population of Germany aged 18–79 years [18].
In addition, the observed number of subjects end stage
renal disease in our sample (n = 1) was similar to the ex-
pected number of subjects with end stage renal disease
(n = 7) as derived from a recent report [26]. To take into
account both the weighting and the correlation of the
participants within a community, confidence intervals
were determined using the survey procedures in SAS®
(SAS Inc., Cary, NC, USA), Version 9.4.
Results
Table 1 shows details about the main characteristics of
the 7001 participants of the DEGS1 study from whom
the GFR was estimated using different eqs. (3364 men
and 3637 women). The median age was 46.9 years (men:
46.4, women: 47.5). The prevalence estimates of persons
with medical history of arterial hypertension and dia-
betes mellitus were 31.5% and 6.6% respectively. Table 2
displays the estimated prevalence of participants with
decreased kidney function, defined as eGFR <60 ml/
min/1.73m2, stratified by sex and age group. Overall, the
prevalence of participants aged 18–79 years with de-
creased kidney function differed considerably depending
on the equation used and was as follows: 2.1% (CKD-
EPIcys), 2.3% (CKD-EPIcrecys), 3.8% (CKD-EPIcre),
5.0% (MDRD), 6.0% (LM) and 6.9% (FAScre). The preva-
lence ranged from 1.6% to 5.6% among men and from
2.6% to 8.2% among women using the CKD-EPIcys
equation and the FAScre equation respectively. What-
ever equation was used, the estimated prevalence was
Fig. 1 Equations used to estimate GFR. MDRD: Modification of Diet in Renal Disease study equation; CKD-EPIcre: Chronic Kidney Disease Epidemiology
Collaboration creatinine equation; CKD-EPIcys: Chronic Kidney Disease Epidemiology Collaboration cystatin C equation; CKD-EPIcrecys: Chronic Kidney
Disease Epidemiology Collaboration creatinine and cystatin C equation; LM: Lund-Malmö equation; FAScre: Full Age Spectrum creatinine equation; Scr:
serum creatinine; Scys: serum cystatin C; min: minimum; max: maximum
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higher for women than for men and increased with age
in both sexes: among participants aged <60 years the
prevalence varied from 0.2% to 1.2% and increased
among participants aged 70 < 80 years up to 11.4% using
CKD-EPIcys and up to 38.4% using FAScre. The mean
eGFR varied from 83.7 using LM to 111.4 using CKD-
EPIcys.
Based on the age specific prevalence estimates and the
German population in 2011, the estimated number of
persons aged 18–79 years with decreased kidney func-
tion in Germany varied from 1.41 m using the CKD-
EPIcys equation to 4.58 m using the FAScre equation.
Assuming that the prevalence of persons aged ≥80 with
decreased kidney function equals that of the study par-
ticipants aged 75 < 80 years, the total number of persons
with decreased kidney function ranged from 2.15 m
using the CKD-EPIcys equation to 6.78 m using the
FAScre equation (Table 3).
Table 1 Characteristics of 7001 adults aged 18–79 in Germany 2008–2011 (DEGS1)
Characteristic Overall Men Women
Sex: N, % 7001 100 3364 49.9 3637 50.1
Age (Years): median (P10, P90) 46.9 (23.6, 70.4) 46.4 (23.3, 69.8) 47.5 (23.9, 70.9)
BMI (Kg/m2): median (P10, P90) 26.2 (21.0, 33.4) 26.7 (22.1, 32.9) 25.4 (20.4, 33.8)
Serum creatinine (mg/dl): median (P10, P90) 0.82 (0.67, 1.06) 0.92 (0.76, 1.13) 0.75 (0.63, 0.90)
Serum cystatin C (mg/l): median (P10, P90) 0.70 (0.57, 0.90) 0.73 (0.61, 0.90) 0.67 (0.55, 0.89)
Medical history
Hypertension: N, % 2585 31.5 1349 33.4 1236 29.7
Diabetes mellitus: N, % 539 6.6 305 7.0 234 6.2
P10 10th percentile, P90 90th percentile, BMI body mass index
Table 2 eGFR and estimated prevalence of decreased kidney function (eGFR <60 ml/min/1.73m2) among 7001 adults aged 18–79 in
Germany 2008–2011 (DEGS1) according to the equation used
eGFR: Mean (SD, CV) Prevalence (95% CI)
Overall <60 years 60 < 69 years 70 < 79 years
Overall N = 7001 N = 4538 N = 1376 N = 1087
MDRD 88.4 (59.3, 0.67) 5.0 (4.3–5.7) 1.2 (0.8–1.5) 10.9 (8.8–13.1) 20.6 (17.3–23.9)
CKD-EPIcre 95.2 (40.9, 0.43) 3.8 (3.3–4.4) 0.4 (0.2–0.6) 7.8 (5.9–9.6) 19.2 (16.1–22.4)
CKD-EPIcys 111.4 (34.3, 0.31) 2.1 (1.7–2.5) 0.2 (0.1–0.3) 3.8 (2.3–5.4) 11.4 (8.9–13.9)
CKD-EPIcrecys 105.1 (34.5, 0.33) 2.3 (1.9–2.7) 0.2 (0.1–0.3) 3.8 (2.2–5.3) 12.8 (10.4–15.3)
LM 83.7 (25.3, 0.43) 6.0 (5.3–6.7) 0.5 (0.3–0.8) 11.7 (9.5–13.8) 31.4 (27.6–35.2)
FAScre 91.7 (54.8, 0.60) 6.9 (6.1–7.6) 0.5 (0.3–0.7) 11.9 (9.9–14.0) 38.4 (34.2–42.5)
Men N = 3364 N = 2150 N = 667 N = 547
MDRD 91.4 (45.7, 0.50) 4.1 (3.3–4.8) 0.9 (0.5–1.3) 9.4 (6.4–12.4) 18.3 (14.4–22.1)
CKD-EPIcre 96.4 (32.2, 0.34) 3.6 (2.9–4.4) 0.5 (.0.2–0.8) 7.7 (4.9–10.4) 19.0 (14.9–23.1)
CKD-EPIcys 113.5 (28.1, 0.25) 1.6 (1.1–2.0) 0.2 (0.0–0.4) 2.8 (0.7–4.8) 8.6 (5.8–11.4)
CKD-EPIcrecys 106.8 (27.6, 0.26) 1.7 (1.3–2.2) 0.3 (0.1–0.5) 2.3 (0.3–4.3) 10.5 (7.6–13.4)
LM 84.0 (28.1, 0.33) 5.6 (4.8–6.5) 0.5 (0.3–0.8) 12.3 (9.1–15.5) 30.5 (25.6–35.5)
FAScre 94.2 (43.8, 0.46) 5.6 (4.7–6.4) 0.4 (0.1–0.6) 11.3 (8.2–14.4) 32.1 (27.0–37.1)
Women N = 3637 N = 2388 N = 709 N = 540
MDRD 85.5 (43.5, 0.51) 5.9 (4.9–6.9) 1.5 (0.9–2.1) 12.4 (9.3–15.5) 22.6 (17.9–27.3)
CKD-EPIcre 94.0 (32.6, 0.35) 4.0 (3.2–4.8) 0.3 (0.1–0.6) 7.8 (5.3–10.4) 19.4 (14.9–24.0)
CKD-EPIcys 109.3 (29.6, 0.27) 2.6 (2.0–3.3) 0.1 (0.0–0.2) 4.9 (2.4–7.4) 13.8 (9.7–17.8)
CKD-EPIcrecys 103.4 (30.0, 0.29) 2.8 (2.2–3.4) 0.1 (0.0–0.1) 5.2 (2.8–7.6) 14.8 (10.9–18.7)
LM 83.4 (27.4, 0.33) 6.4 (5.4–7.3) 0.5 (0.2–0.9) 11.1 (8.2–14.0) 32.2 (27.2–37.1)
FAScre 89.3 (40.8, 0.46) 8.2 (7.1–9.2) 0.5 (0.2–0.9) 12.6 (9.7–15.5) 43.6 (38.3–49.0)
SD standard deviation, CV coefficient of variation, CI confidence interval, MDRD Modification of Diet in Renal Disease study equation, CKD-EPIcre Chronic Kidney
Disease Epidemiology Collaboration creatinine equation, CKD-EPIcys Chronic Kidney Disease Epidemiology Collaboration cystatin C equation, CKD-EPIcrecys Chronic
Kidney Disease Epidemiology Collaboration creatinine and cystatin C equation, LM Lund-Malmö equation, FAScre Full Age Spectrum creatinine equation
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Figure 2 presents the prevalence estimates of the GFR
categories according to the equation used. Using any
CKD-EPI equations, the large majority of the partici-
pants were classified as G1. In particular, according to
CKD-EPIcys, almost 9 out of 10 participants were classi-
fied in this category. Using MDRD or LM the highest
prevalence was estimated for the participants with eGFR
60 < 90 ml/min/1.73m2 (category: G2). The prevalence of
participants with eGFR <45 ml/min/1.73m2 (category
G3b-G5) varied from 0.7% using CKD-EPIcys to 1.4%
using FAScre.
Table 4 shows that great absolute differences between
eGFR were calculated comparing CKD-EPIcys with LM
(md = 27.6), CKD-EPIcys with MDRD (md = 22.9) and
CKD-EPIcrecys with LM (md = 21.4). In contrast, small
differences were calculated comparing FAScre with
MDRD (md = 3.3) and CKD-EPIcre (md = 3.5), MDRD
with LM (md = 4.7), CKD-EPIcys with CKD-EPIcrecys
(md = 6.2) and CKD-EPIcre with MDRD (md = 6.8).
Overall, the absolute md between eGFR were very small
for small values of eGFR and increased considerably
with increasing eGFR values. In particular, among
Table 3 Estimated numbers (millions) of adults with decreased kidney function (eGFR <60 ml/min/1.73m2) in Germany 2011
according to the equation used
Age (years) MDRD CKD-EPIcre CKD-EPIcys CKD-EPIcrecys LM FAScre
<50 0.179 0.039 0.036 0.022 0.041 0.016
50 < 60 0.373 0.162 0.037 0.058 0.214 0.199
60 < 70 0.944 0.665 0.324 0.320 0.999 1.018
70 < 80 1.772 1.672 1.015 1.119 2.773 3.349
≥80a 1.067 1.070 0.742 0.737 1.930 2.202
Overall 4.335 3.608 2.154 2.256 5.958 6.784
MDRD Modification of Diet in Renal Disease study equation, CKD-EPIcre Chronic Kidney Disease Epidemiology Collaboration creatinine equation, CKD-EPIcys
Chronic Kidney Disease Epidemiology Collaboration cystatin C equation, CKD-EPIcrecys Chronic Kidney Disease Epidemiology Collaboration creatinine and cystatin
C equation, LM Lund-Malmö equation, FAScre: Full Age Spectrum creatinine equation
aBy use of the estimated prevalence of study participants aged 70 < 80 years
Fig. 2 Prevalence estimates of GFR categories among 7001 adults aged 18–79 in Germany 2008–2011 (DEGS1) according to the equation used.
MDRD: Modification of Diet in Renal Disease study equation; CKD-EPIcre: Chronic Kidney Disease Epidemiology Collaboration creatinine equation;
CKD-EPIcys: Chronic Kidney Disease Epidemiology Collaboration cystatin C equation; CKD-EPIcrecys: Chronic Kidney Disease Epidemiology
Collaboration creatinine and cystatin C equation; LM: Lund-Malmö equation; FAScre: Full Age Spectrum creatinine equation
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participants with mean eGFR <45 ml/min/1.73m2 (G3b-
G5), the md ranged from 0.1 (MDRD vs. FAScre) to
6.1 ml/min/1.73m2 (CKD-EPIcys vs. LM), while among
participants with mean eGFR >90 ml/min/1.73m2 (G1)
the md ranged from 2.2 (CKD-EPIcre vs. FAScre) to
30.1 ml/min/1.73m2 (CKD-EPIcys vs. LM). Very good
levels of agreement between the equations for small
values of eGFR were shown also from the Bland-Altman
plots that depict the agreement over the whole range of
eGFR values (Figs. 3 and 4, and Additional file 1: Figure
S1). The greatest variability of the differences between
eGFR, estimated as the range between the limits of the
agreement, was observed comparing CKD-EPIcys with
MDRD (95% CI: -97.6, 143.5).
Discussion
This study shows that prevalence estimates of decreased
kidney function (eGFR <60 ml/min/1.73m2) among
adults varies considerably depending on the equation
used for estimating GFR. Prevalence estimates among of
persons aged 18–79 in Germany 2008–2011 (DEGS1)
varied from 2.1% using CKD-EPIcys to 6.9% using FAS-
cre and the overall number of persons with decreased
kidney function ranged accordingly from 2.15 m (CKD-
EPIcys) to 6.78 m (FAScre). From a public health stand-
point, the choice of the equation produces a wide range
of the estimated number of persons with kidney disease
in Germany.
Prevalence estimates of decreased kidney function vary
substantially both within and between countries and
many potential factors leading to these variations have
been discussed [27–29]. Our estimated prevalence is
lower than those from the SHIP-1 study and the KORA
F4 study, which reported a prevalence of decreased kid-
ney function in Northeast and Southern Germany of
5.9% and 3.1% respectively using CKD-EPIcrecys (vs.
2.3% in DEGS1) [16]. If compared with DEGS1, the me-
dian age of participants as well as the prevalence of
hypertension and diabetes mellitus in these studies was
considerably higher, especially for SHIP-1. Therefore, the
observed differences are mostly due to differences in age
and in prevalence of risk factors among the study popu-
lations. Prevalence estimates in our study were also
lower than those from the US population based on the
National Health and Nutrition Examination Survey
(NHANES), which reported a prevalence estimate of 8%
using MDRD [2]. Some reasons for these differences
have been discussed in our previous publication, includ-
ing heterogeneity in age distribution and ethnic charac-
teristics of the study populations [15].
As the GFR estimating equations include the same
demographic variables, such as age and sex, the
Table 4 Absolute mean differences between GFR estimated by the different equations used among 7001 adults aged 18–79 in
Germany 2008–2011 (DEGS1) according to GFR category
Overall GFR categorya
G1 G2 G3a G3b-G5
MDRD vs. CKD-EPIcrecys 16.7 (15.9%) 17.5 (15.1%) 16.1 (18.3%) 6.4 (11.1%) 2.2 (6.0%)
MDRD vs. CKD-EPIcre 6.8 (7.1%) 7.1 (6.6%) 6.9 (8.4%) 1.7 (3.1%) 0.3 (0.8%)
MDRD vs. CKD-EPIcys 22.9 (20.6%) 24.3 (20.4%) 20.0 (22.2%) 4.6 (8.2%) 3.5 (9.1%)
MDRD vs. LM 4.7 (5.6%) 9.6 (9.9%) 1.5 (1.9%) 1.4 (2.6%) 2.6 (7.7%)
MDRD vs. FAScre 3.3 (3.6%) 5.1 (4.7%) 2.0 (2.5%) 2.9 (5.5%) 0.1 (0.1%)
CKD-EPIcrecys vs. CKD-EPIcre 9.9 (10.4%) 10.1 (9.8%) 9.8 (13.2%) 5.4 (10.6%) 1.9 (5.4%)
CKD-EPIcrecys vs. CKD-EPIcys 6.2 (5.6%) 6.6 (5.7%) 4.3 (5.3%) 1.1 (2.0%) 0.8 (2.3%)
CKD-EPIcrecys vs. LM 21.4 (25.6%) 24.0 (26.1%) 17.6 (24.8%) 8.3 (16.6%) 4.8 (14.9%)
CKD-EPIcrecys vs. FAScre 13.4 (14.6%) 12.6 (12.3%) 16.2 (22.8%) 9.4 (19.0%) 2.0 (5.6%)
CKD-EPIcre vs. CKD-EPIcys 16.1 (14.5%) 16.8 (14.2%) 14.6 (16.8%) 3.5 (6.2%) 3.4 (9.0%)
CKD-EPIcre vs. LM 11.5 (13.7%) 15.0 (15.8%) 8.2 (11.0%) 3.3 (6.3%) 2.9 (8.9%)
CKD-EPIcre vs. FAScre 3.5 (3.8%) 2.2 (2.1%) 5.6 (7.4%) 4.6 (8.9%) 0.4 (1.1%)
CKD-EPIcys vs. LM 27.6 (33.0%) 30.1 (33.5%) 22.1 (32.2%) 7.0 (13.9%) 6.1 (18.7%)
CKD-EPIcys vs. FAScre 19.7 (21.4%) 19.4 (19.4%) 22.3 (32.7%) 8.0 (16.0%) 3.0 (8.7%)
LM vs. FAScre 8.0 (8.7%) 13.5 (12.4%) 3.5 (4.4%) 1.2 (2.3%) 2.1 (5.7%)
Relative changes (%) of the estimated GFR were calculated as ([first value] – [second value]) / [second value])
MDRD Modification of Diet in Renal Disease study equation, CKD-EPIcre Chronic Kidney Disease Epidemiology Collaboration creatinine equation, CKD-EPIcys
Chronic Kidney Disease Epidemiology Collaboration cystatin C equation, CKD-EPIcrecys Chronic Kidney Disease Epidemiology Collaboration creatinine and cystatin
C equation, LM Lund-Malmö equation, FAScre Full Age Spectrum creatinine equation
aGFR categories are defined according to the mean value of GFR estimated by the equations being compared (expressed in ml/min/1.73m2) as follows: G1: ≥90,
G2: 60 < 90, G3a: 45 < 60, G3b-G5: <45
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observed differences between prevalence estimates could
be mainly due to the fact that some equations use serum
cystatin C (CKD-EPIcys, CKD-EPIcrecys), while other
equations use serum creatinine alone as biomarker
(MDRD, CKD-EPIcre, LM and FAScre). In particular,
the prevalence of participants with decreased kidney
function estimated by those equations that include
serum cystatin C was considerably lower than the preva-
lence estimated by those equations based on serum cre-
atinine alone. The lowest prevalence was estimated
using the equation that includes cystatin C alone as la-
boratory parameter (CKD-EPIcys). These results are in
line with published findings [30] and may reflect that
there are less non-renal factors influencing cystatin C
plasma levels than there are for creatinine plasma levels.
Higher prevalence estimates using equations with cre-
atinine alone were found also by the Berlin Initiative
Study (BIS) for people aged 70 years and older [17]. In
contrast to our study, data based on NHANES showed
that equations with creatinine alone yielded lower
Fig. 3 Bland-Altman plots for comparison between equations that include cystatin C and equations based on creatinine alone among 7001
adults aged 18–79 in Germany 2008–2011 (DEGS1). MDRD: Modification of Diet in Renal Disease study equation; CKD-EPIcre: Chronic Kidney
Disease Epidemiology Collaboration creatinine equation; CKD-EPIcys: Chronic Kidney Disease Epidemiology Collaboration cystatin C equation;
CKD-EPIcrecys: Chronic Kidney Disease Epidemiology Collaboration creatinine and cystatin C equation; LM: Lund-Malmö equation. Solid, horizontal
lines represent the mean difference between the eGFR. Dashed, horizontal lines represent the limit of agreement between the equations. Solid,
vertical lines represent the eGFR cut-off value for a decreased kidney function (60 ml/min/1.73m2)
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prevalence estimates if compared with equations that in-
cluded cystatin C [31]. Interestingly, in agreement with
DEGS1, NHANES reported higher mean values of eGFR
for equations with cystatin C if compared with mean
eGFR calculated by equations with creatinine alone.
Our data point out that the seemingly low level of
imprecision of the creatinine based calculations may
translate into quite relevant differences when using
the equations for epidemiological questions and sup-
port the suggestion to use the GFR values estimated
by equations with cystatin C as confirmatory test for
people with decreased kidney function as estimated
by equations with creatinine only [4].
Given the large difference between the prevalence
estimates yielded by the different GFR estimating
equations, the choice for the equation for assessing
GFR can have a great impact on the assessment of
public health implications, e. g. projections of disease
burden or medical resources in relation to CKD.
Individually, misclassification of patients as having
chronic kidney disease can result in unnecessary diag-
nostic and therapeutic interventions with consequent
added costs to the health care system. Actually, the
costs of cystatin C tests vary from about 3 to 20
times those of creatinine tests [32]. It is well known
that any estimating equation performs better in those
populations which are alike the population in which
the equation was developed. For example, the CKD-
EPIcre equation was validated in a population with a
majority of healthy people and therefore this equation
provides accurate estimates at higher ranges of eGFR.
In contrast, as the MDRD equation was developed in
patients with CKD, this equation performs better in
populations with lower eGFR. Finally, the BIS2 equa-
tion was explicitly designed to accurately estimate
GFR in persons aged 70 years or older and should be
therefore used in older populations. Therefore, in
order to minimize errors in GFR estimations and to
reduce the risk of misclassification the equation
should be used for which the development population
matches best with the population of interest. In our
study, great differences between eGFR were calculated
by comparing equations that include cystatin C
(CKD-EPIcrecys, CKD-EPIcys) with equations based
Fig. 4 Bland-Altman plots for comparison between equations both based on cystatin C and comparison between equations both based on
creatinine alone among 7001 adults aged 18–79 in Germany 2008–2011 (DEGS1). MDRD: Modification of Diet in Renal Disease study equation; CKD-
EPIcre: Chronic Kidney Disease Epidemiology Collaboration creatinine equation; CKD-EPIcys: Chronic Kidney Disease Epidemiology Collaboration
cystatin C equation; CKD-EPIcrecys: Chronic Kidney Disease Epidemiology Collaboration creatinine and cystatin C equation; LM: Lund-Malmö equation.
Solid, horizontal lines represent the mean difference between the eGFR. Dashed, horizontal lines represent the limit of agreement between the
equations. Solid, vertical lines represent the eGFR cut-off value of a decreased kidney function (60 ml/min/1.73m2)
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on creatinine alone (MDRD, CKD-EPIcre, LM and
FAScre). However, the analysis of the agreement be-
tween the equations stratified by the mean values of
eGFR shows that the absolute and relative change
(percent change) of eGFR was larger among GFR cat-
egories G1 and G2 than G3b-G5. In particular, the
systematic differences between eGFR among partici-
pants classified in the category G3b-G5 can be easily
considered clinically not relevant. The Bland-Altman
plots showed a similar distribution pattern, with good
agreement between the estimating equations for low
values of eGFR and increasing systematic differences
with increasing eGFR. These results are consistent
with those observed in other studies [33, 34] and
suggest that the different estimating equations may be
used interchangeably among persons with moderately
to severely decreased kidney function (eGFR: <45 ml/
min/1.73m2). Furthermore, high variability of the
differences, estimated by the limits of the agreement
between the equations, was observed by comparing
CKD-EPIcys with equations based on creatinine alone.
This study has some limitations: First, as we did not
measure the GFR by a gold standard, we could not
determine which equation provides the most valid
prevalence estimates of decreased kidney function for
the German population. Second, information on place of
residence of the study participants was not available and
we could not therefore evaluate regional variability in
prevalence estimates. Third, as the first wave of the
DEGS study was conducted from 2008 to 2011, serum
cystatin C concentration was measured using a not stan-
dardized assay which complicates the comparison with
studies that used a standardized assay for cystatin C. A
further limitation of our and other cross-sectional stud-
ies is the lack of a second GFR estimation after 3 months
which most likely results in a false positive prevalence of
kidney dysfunction.
Conclusions
Our study illustrates the importance of the choice of
the GFR estimating equation from an epidemiological
point of view. Prevalence estimates of decreased kidney
function in Germany are highly related to the equation
used. In particular, the equations that include serum
cystatin C provide lower prevalence estimates if
compared with those based on serum creatinine alone.
However, the analysis of the systematic differences
between the eGFR suggests that the equations could be
used interchangeably among persons with pronounced
decreased kidney function. Additional longitudinal
epidemiological studies are needed to investigate
which of the available equations are most useful for
prediction of CKD and associated complications at
the population level.
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